Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck × Ramucirumab × 90 days × Clear all

NCT05980000 2026-02-06

Rambro2

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03650764 2025-12-30

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck